Aspirin for Secondary Prevention of Cardiovascular Disease in 51 Low-, Middle-, and High-Income Countries

• Type: Article in International Scientific Journal
• Date: 2023

Authors

Yoo, SGK (Author) Other; Chung, GS (Author) Other; Bahendeka, SK (Author) Other; Sibai, AM (Author) Other; Damasceno, A (Author) Other; Farzadfar, F (Author) Other; Rohloff, P (Author) Other; Houehanou, C (Author) Other; Norov, B (Author) Other; Karki, KB (Author) Other; Azangou-Khyavy, M (Author) Other; Marcus, ME (Author) Other; Aryal, KK (Author) Other; Brant, LCC (Author) Other; Theilmann, M (Author) Other; Cifková, R (Author) Other; Lunet N (Author) FMUP; Gurung, MS (Author) Other; Mwangi, JK (Author) Other; Martins, J (Author) Other; Haghshenas, R (Author) Other; Sturua, L (Author) Other; Vollmer, S (Author) Other; Bärnighausen, T (Author) Other; Atun, R (Author) Other; Sussman, JB (Author) Other; Singh, K (Author) Other; Moghaddam, SS (Author) Other; Guwatudde, D (Author) Other; Geldsetzer, P (Author) Other; Manne-Goehler, J (Author) Other; Huffman, MD (Author) Other; Davies, JI (Author) Other; Flood, D (Author) Other

Journal

Title: JAMA - Journal of the American Medical Association

Vol. 330

Pages: 715-724

ISSN: 0098-7484

Publisher: American Medical Association

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 2 Citations

Other information

Authenticus ID: P-010-71D

DOI: 10.1001/jama.2023.12905

Abstract (EN): IMPORTANCE Aspirin is an effective and low-cost option for reducing atherosclerotic cardiovascular disease (CVD) events and improving mortality rates among individuals with established CVD. To guide efforts to mitigate the global CVD burden, there is a need to understand current levels of aspirin use for secondary prevention of CVD. OBJECTIVE To report and evaluate aspirin use for secondary prevention of CVD across low-, middle-, and high-income countries. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional analysis using pooled, individual participant data from nationally representative health surveys conducted between 2013 and 2020 in 51 low-, middle-, and high-income countries. Included surveys contained data on self-reported history of CVD and aspirin use. The sample of participants included nonpregnant adults aged 40 to 69 years. EXPOSURES Countries' per capita income levels and world region; individuals' socioeconomic demographics. MAIN OUTCOMES AND MEASURES Self-reported use of aspirin for secondary prevention of CVD. RESULTS The overall pooled sample included 124 505 individuals. The median age was 52 (IQR, 45-59) years, and 50.5% (95% CI, 49.9%-51.1%) were women. A total of 10 589 individuals had a self-reported history of CVD (8.1% [95% CI, 7.6%-8.6%]). Among individuals with a history of CVD, aspirin use for secondary prevention in the overall pooled sample was 40.3% (95% CI, 37.6%-43.0%). By income group, estimates were 16.6% (95% CI, 12.4%-21.9%) in low-income countries, 24.5% (95% CI, 20.8%-28.6%) in lower-middle-income countries, 51.1% (95% CI, 48.2%-54.0%) in upper-middle-income countries, and 65.0% (95% CI, 59.1%-70.4%) in high-income countries. CONCLUSION AND RELEVANCE Worldwide, aspirin is underused in secondary prevention, particularly in low-income countries. National health policies and health systems must develop, implement, and evaluate strategies to promote aspirin therapy.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 10